Advertisement

Gastro-News

, Volume 5, Issue 6, pp 52–57 | Cite as

DDW-Kongress 2018 in Washington DC — Teil 3

Die aktuellen Studien zu Kolon, — Dünndarm und CED

  • Birgit Terjung
  • Manfred Gross
aktuell
  • 3 Downloads

Die chronisch entzündlichen Darmerkrankungen waren wie in den vergangenen Jahren das größte Thema auf dem amerikanischen Gastroenterologenkongress (DDW). Daneben gab es aber auch wichtige wissenschaftlichen Erkenntnisse zu den sonstigen Darmerkrankungen einschließlich der funktionellen Störungen. In einer Serie von Artikeln werden in GASTRO NEWS die Inhalte der wichtigsten Vorträge und Abstracts präsentiert.

Literatur

  1. 1.
    Mahadev S et al. Gastroenterology 2018; 154(6) Suppl1: Mo1035CrossRefGoogle Scholar
  2. 2.
    Fan C et al. Gastroenterology 2018; 154(6) Suppl1: Sa1081Google Scholar
  3. 3.
    Iacovou M et al. Gastroenterology 2018; 154(6) Suppl1: Sa2003CrossRefGoogle Scholar
  4. 4.
    Wilkinson-Smith V et al. Gastroenterology 2018; 154(6), Suppl 1: Mo1053Google Scholar
  5. 5.
    Eady et al. Gastroenterology 2018; 154(6) Suppl1: Su1189CrossRefGoogle Scholar
  6. 6.
    Cremon C et al. Gastroenterology 2018; 154(6), Suppl 1: Su1659Google Scholar
  7. 7.
    Du et al. Gastroenterology 2018; 154 (6) Suppl1: LB Tu2017Google Scholar
  8. 8.
    Botschuijver S et al. Gastroenterology 2018; 154(6), Suppl 1: OP643CrossRefGoogle Scholar
  9. 9.
    Manssor et al. Gastroenterology 2018;154(6), Suppl 1:Mo1617Google Scholar
  10. 10.
    Ohri A et al. Gastroenterology 2018; 154(6) Suppl1: Sa1634Google Scholar
  11. 11.
    Vuik FE et al. Gastroenterology 2018; 154(6) Suppl1: Sa1635CrossRefGoogle Scholar
  12. 12.
    Vasopelli R, Kerstin Schuette K, Schulz K et al. Distinct microbiotica communities along the entire human digestive tract. Gastroenterology 2018; 154 (6) Suppl1: Su1950Google Scholar
  13. 13.
    Bharat M, Curran J, Herfarth HH et al. SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in placebo controlled, double-blind randomized trial in patients with active mild-to-moderate ulcerative colitis. Gastroenterology 2018; 154(6) Suppl 1: LB OP85CrossRefGoogle Scholar
  14. 14.
    Simpson HL, Campbell BJ. Dietary fibre - microbiotica interactions. Aliment Pharmacol Therapeut 2015: 42(2): 158–179CrossRefGoogle Scholar
  15. 15.
    Schreiner P, Yilmaz B, Franc Y et al. Vegetarian and gluten-free diet in patients with IBD - associated with a different microbiotica compared to omnivore IBD patients. Gastroenterology 2018; 154(6) Suppl 1: Sa1864CrossRefGoogle Scholar
  16. 16.
    Costello SP, Soo W, Bryant R V. et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 2017. doi:  https://doi.org/10.1111/apt.14173Google Scholar
  17. 17.
    Holvoet T, Joossens M, Jerina B et al. Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled clinical trial. Gastroenterology 2018; 154(6) Suppl1: OP617CrossRefGoogle Scholar
  18. 18.
    Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017. doi:  https://doi.org/10.1136/gutjnl-2016-313017Google Scholar
  19. 19.
    Pariente B, Cosnes J, Danese S et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011. doi:  https://doi.org/10.1002/ibd.21506Google Scholar
  20. 20.
    Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017. doi:  https://doi.org/10.1016/S0140-6736(17)32641-7Google Scholar
  21. 21.
    Ungaro R, Colombel F, Patel A et al. Net remission rates with biologic treatment in Crohn’s diesease: a reappraisal of the clinical data adjusting for both induction and remission phases and prior exposure to TNF-antagonists. Gastroenterology 2018; 154(6) Suppl1: Mo 1035Google Scholar
  22. 22.
    Kucharzik, Torsten; Dignass, Axel U; Atreya A et al. Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2018; 56:1087–1169CrossRefGoogle Scholar
  23. 23.
    Dreesen E, D’Haens GR, Baert F et al. Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic-pharmacodynamic analysis of TAILORIX. Gastroenterology 2018; 154(6) Suppl 1: Mo1841Google Scholar
  24. 24.
    Singh N, Arora Y, Yakub J et al. Infliximab trough levels predict one year persistent remission in infliximab-treated pediatric IBD patients. Gastroenterology 2018; 154(6) Suppl1: Mo1851Google Scholar
  25. 25.
    Syal G, Robbins L, Kashani A et al. Hypalbuminemia and bandemia predict failure of infliximab rescue therapy in acute severe colitis independent of the infliximab dose. Gastroenterology 2018; 154(6) Suppl1: Mo1891CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.GFO Klinikum Bonn, St. Josef HospitalBonnDeutschland
  2. 2.Internistisches Klinikum München SüdMünchenDeutschland

Personalised recommendations